We PAID Act
Latest action · Jul 31, 2019 Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedJul 31, 2019
- Passed SenateNot reached
- Passed HouseNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
We Protect American Investment in Drugs Act or the We PAID Act
This bill limits the price of certain prescription drugs that rely on patents developed with federal support.
The bill requires the Department of Health and Human Services to contract with the National Academy of Medicine to conduct a study for determining the reasonableness of the price of such prescription drugs. The bill also establishes the Drug Affordability and Access Committee, which must use the study to develop a methodology and then determine whether the price of each applicable drug is reasonable after the drug enters the market.
Further, the bill establishes certain pricing requirements for such prescription drugs. First, the manufacturer must submit to the committee the list and retail prices for the drug as well as specified expenditure information. Second, after a drug is on the market for one year, the manufacture must set the drug’s list price at no more than the committee’s reasonable price determination. Third, subsequent price increases are capped at the annual percentage change in the medical care consumer price index for prescription drugs. The penalties for noncompliance with these requirements include expiration of marketing exclusivity, fines, and prohibitions on entering licensing agreements for the applicable drug.
Additionally, the bill revises the patent application requirements for drugs to include the disclosure of specified federal grants.
Cosponsors 1
Members who signed on, in the order they did. All signed on Jul 31, 2019.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| R-FL | Rick Scott | Original | Jul 31, 2019 |
Committees 1
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| Senate | Health, Education, Labor, and Pensions Committee | Referred Jul 31, 2019 |
Actions 2
Everything that happened, newest first.
- Jul 31, 2019Introduced in Senate
- Jul 31, 2019Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Research
What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.
CRS reports 1
Congressional Research Service work that CRS links to this bill or the law it became, newest first.
Cite it 1
Products on other subjects that cite it, usually among other measures.
| Product | Title | Kind | Published |
|---|---|---|---|
| R46741 | Drug Pricing and Intellectual Property: The Legislative Landscape for the 117th Congress | Report | Mar 31, 2021 |
Titles 3
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- A bill to establish a process by which reasonable drug prices may be determined, and for other purposes.
- Short Title(s) as Introduced
- We PAID Act
- We Protect American Investment in Drugs Act
Subjects
Assigned by the Library of Congress. Policy area: Health.
- Business ethics
- Business records
- Civil actions and liability
- Competition and antitrust
- Congressional oversight
- Government ethics and transparency, public corruption
- Government information and archives
- Government studies and investigations
- Health
- Health care costs and insurance
- Health programs administration and funding
- Health technology, devices, supplies
- Inflation and prices
- Intellectual property
- Licensing and registrations
- Medical research
- Prescription drugs
- Public contracts and procurement
- Research administration and funding
- Research and development
- Retail and wholesale trades
- Tax-exempt organizations
Text 1
Each version as it was printed, newest first.
- Jul 31, 2019Introduced in Senate
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.
